糖皮质激素联合支气管扩张剂治疗哮喘长期控制不佳患者的临床作用分析

王添

[关键词] 哮喘;长期控制不佳;糖皮质激素;支气管扩张剂;临床作用

[中图分类号] R562          [文献标识码] B          [文章編号] 1673-9701（2021）21-0090-03

Analysis on the clinical efficacy of glucocorticoid combined with bronchodilator in the treatment of asthma patients with long term poor control

WANG Tian

Department of Infectious Disease，the Second Affiliated Hospital of Shenyang Medical College， Shenyang 110002， China

[Abstract] Objective To explore the clinical efficacy of glucocorticoid combined with bronchodilator in the treatment of asthma patients with long term poor control. Methods A total of 100 asthma patients with long term poor control admitted to and treated in our hospital from January 2018 to June 2020 were selected for research， and they were divided into the control group （n=50） and the observation group （n=50） according to the random number table method. The control group was treated with bronchodilator， while the observation group was treated with glucocorticoid on the basis of the control group. The clinical efficacies of the two groups were appraised， the asthma control test （ACT） scores before and after treatment were evaluated， the levels of serum interleukin-4（IL-4） and interleukin-8 （IL-8） before and after treatment were detected，and the results between the two groups were compared and analyzed. Results The total effective rate of the observation group was 98.00%，which was higher than 80.00% of the control group（P<0.05）. Before treatment，there was no statistically significant differences in ACT scores， levels of serum IL-4 and IL-8 between the two groups （P>0.05）. After treatment， the ACT scores， levels of serum IL-4 and IL-8 of the observation group were （4.32±0.42） points， （12.10±3.42） ng/L，（70.69±5.94）ng/L， while those of the control group were （3.41±0.55）points， （18.75±5.43）ng/L， （90.04±6.85） ng/L， respectively，with statistically significant differences between the two groups（P<0.05）. Conclusion Long term poorly controlled asthma can be treated with glucocorticoid combined with bronchodilator， which can improve the therapeutic efficacy， ACT score and serum inflammatory index， and is worthy of application.

[Key words] Asthma; Long term poor control; Glucocorticoid; Bronchodilator; Clinical efficacy

哮喘也称支气管哮喘，是临床常见呼吸科疾病，是多种细胞或细胞组分导致的慢性气道炎症病变，可进而诱发气道反应性增高。哮喘患者多有气促、咳嗽、喘息等症状，且症状好发于夜间、凌晨，对患者的睡眠质量造成严重影响，进而影响他们正常的学习、工作和生活，导致生活质量降低[1]。李倩倩等[2]研究发现哮喘还受遗传因素、环境因素、病毒感染、精神因素等的影响，因此在临床生活中应做好防控，尽量减少哮喘发生，一旦罹患此病，药物治疗是首选疗法，但不同的药物治疗效果不一，且单用药物方案治疗控制效果不佳，尤其是老年患者合并基础疾病较多，病情较重，治疗难度大，复发率高[3]。目前从临床治疗来看，哮喘长期控制不佳患者是治疗的重难点，随着近几年联合用药方案的指征扩大，在一些报道中发现联合用药可提高预后，成为研究热点。为进一步探究哮喘长期控制不佳患者应用糖皮质激素联合支气管扩张剂治疗的临床作用，我院对2018年1月至2020年6月收治的100例患者进行分组研究，现报道如下。